Startup Creative Bio launches cell culture portfolio
Creative Bio has launched a portfolio of cell culture tools that it hopes will be useful during the COVID-19 pandemic.
IGM Biosciences licenses SARS-CoV-2 antibodies from AvantGen
AvantGen has licensed a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
ImmunityBio licenses oral vaccine tech from IosBio
ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated in trials of ImmunityBio's second-generation human adenovirus 5 (hAd5) COVID-19 vaccine candidate.
Codagenix starts phase I trial for COVID-19 vaccine in U.K.
The first patient has been dosed in a phase I clinical trial being conducted by Codagenix and the Serum Institute of India of COVI-VAC, a single-dose, intranasal vaccine against the SARS-CoV-2 virus.
How can biopharma innovation be maintained after COVID-19?
Will the speed of biotech innovation seen during the COVID-19 pandemic be maintained going forward, or will the market revert to the status quo? A panel of speakers discussed these questions during a January 7 advance session of the Biotech Showcase, a virtual event to be held January 11-15.  Discuss
U.K. authorizes Moderna COVID-19 vaccine
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Moderna's messenger RNA (mRNA) COVID-19 vaccine, mRNA-1273, for use under Regulation 174.
CureVac, Bayer partner on COVID-19 vaccine
CureVac and Bayer have signed a collaboration and services agreement to develop a new class of medicines based on messenger RNA, starting with CureVac's COVID-19 vaccine candidate, CVnCoV.
MilliporeSigma acquires AmpTec
MilliporeSigma has purchased messenger RNA firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture messenger RNA for use in COVID-19 vaccines and treatments.
EC authorizes Moderna's COVID-19 vaccine
The European Commission (EC) has granted a conditional marketing authorization for Moderna's messenger RNA (mRNA) COVID-19 vaccine, mRNA-1273. The authorization allows vaccination programs using the Moderna vaccine to be rolled out across the European Union.
Top Operation Warp Speed official shares lessons learned from COVID-19
The global COVID-19 pandemic has placed an urgent burden on governments to serve society, and with the help of the biotechnology and pharmaceutical industries, the job is getting done. That's according to Moncef Slaoui, PhD, chief adviser of the U.S. government's Operation Warp Speed project, who discussed his unique experiences at an advance session of the Biotech Showcase virtual event on January 5.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter